Jakarta, CNBC Indonesia – Vaccine for Covid-19, diseases caused new corona virus, is being developed by many parties throughout the world amid a rapid increase in cases. One of them is by the Swedish-English company AstraZeneca and Oxford University.
Their vaccine called AZD1222 has entered Phase III human trials. Large-scale trials have been conducted to assess whether the vaccine can protect from COVID-19. The good news, the test results will be published on July 20, said the medical journal The Lancet, Wednesday (07/15/2020).
“We hope that this paper, which is undergoing final editing and preparation, will be published on Monday, July 20, for an immediate release,” said a spokeswoman for the journal.
However, the company also has not released the results of a Phase I trial, which will indicate whether the vaccine will be safe and whether it induces an immune response or not. Earlier, Lancet said that a report on Phase I research would likely be released this Thursday.
Earlier this month, they had said that the vaccine had successfully elicited an immune response in trials so far and hoped to publish Phase 1 data by the end of July.
“Preclinical trials in pigs previously showed that two doses produce antibody responses that are greater than a single dose,” he explained.
Progress in developing such vaccines is good news for the world, which is being hit by the epidemic of COVID-19. Where the plague originated from Wuhan, China has infected nearly 14 million people worldwide.
There are currently more than 100 vaccines being developed and tested around the world to try to stop the COVID-19 pandemic, which has killed hundreds of thousands of people and damaged the global economy.
The chief scientist of the World Health Organization (WHO) said in June that AstraZeneca’s AZZ1222 was probably the most advanced vaccine in its development.
The company has signed agreements with governments around the world to supply vaccines if they prove effective.
On the other hand, researchers in the United States (US) also reported good news on Tuesday, namely that the experimental vaccine Moderna Inc. was safe to use and triggered an immune response in all (45) healthy volunteers in the initial ongoing study.
Moderna began Phase II trials in May and hopes to start Phase III trials on July 27.
(nothing nothing)
–
